Event Listing

Simon is a Director in the patents group at Murgitroyd, where he leads the Cambridge and central London offices. Simon enjoys a broad range of biotechnology, pharmaceutical and medical device work, as well as SPC and plant variety work. Simon serves client needs in both non-contentious and contentious matters, including oppositions and appeals. Simon joined the patent profession in 2008 following an 11-year academic career, which included a PhD and postdoc at University College London, a postdoc at Cornell University Medical College in New York City, and a postdoc at the MRC Laboratory of Molecular Biology in Cambridge.

Terence is a Senior Patent Attorney at Murgitroyd in their Cardiff Office and leads their Artificial Intelligence team. Terence came into the profession in 2009 and is experienced in patent drafting and prosecution, especially in the software space, but also takes a keen interest in the nuances around procedure at both the UKIPO and the EPO and has often provided training to junior fee earners and support staff on patent formalities.

Sally brings over 25 years of extensive experience across both private practice and in-house roles, most recently leading GSK’s Global Pharma Patents team. Prior to her tenure at GSK, Sally held significant IP leadership roles at AstraZeneca for over a decade and served as Head of IP for a UK biotech. Her expertise spans the entire patent life cycle, from early-stage R&D to end of patent life, and Sally and her teams have been responsible for building and defending patent portfolios for multi-billion dollar assets across the biopharmaceutical industry. With significant exposure to M&A and licensing deals Sally has built a wealth of experience across patent and other exclusivities that define Loss of Exclusivity (LoE) for an asset.

Simeon is Communications Lead for the One IPO Transformation Programme. He has worked in public sector communications for 15 years, having previously worked in a variety of comms roles at the Office for National Statistics and UK Statistics Authority. Simeon joined the IPO in 2020 and acts as a key link between IPO developers and customers. In his spare time, Simeon is an avid gamer and a Tae Kwon-do instructor.

Chris is Patent Subject Matter Expert for the One IPO Transformation Programme. This involves working with the development team and the wider IPO to help ensure that the new system meets the IPO’s needs. He has been a patent examiner for over 20 years, working primarily on chemical applications. Outside of work, Chris enjoys watching a wide variety of sports and is a fan of Coventry City.

Dr Bobby Mukherjee, Chief Counsel, IP & Technology Law – BAE Systems plc and Past President (2012-2014) of the IP Federation. He was the Chartered Institute of Patent Attorneys (CIPA) President for 2025. He previously served and currently sits on CIPA Council, and chaired the CIPA Internal Governance Committee in its formative stage.

Bobby is a qualified UK and European patent attorney with over 28 years’ experience of IP gained in private practice and at BAE Systems plc. He is currently the Head of IP (2009 -) at BAE Systems plc (a FTSE 30 company), which has one of the largest in-house IP teams in the UK.

Bobby has been named a Corporate IP Star by Managing Intellectual Property every year since 2015.

Simon has a Chemistry (with Biochemistry) degree from Bristol University and qualified as a UK patent attorney in 1990. He became a European Patent Attorney in 1992 while with Kilburn & Strode and joined J A Kemp in 1994. He became a partner in J A Kemp’s biotechnology group in 2005 and moved to Schlich on the south coast in January 2022.

Simon handles patent and trade mark work in a wide variety of life science, chemical and pharma fields, including stem cells, human genes and genomics, drug delivery systems, contrast agents, GM crops, algae technology and CRISPR technology. He also handles mechanical work ranging from drones to electric vehicle charging. He works for a broad variety of clients ranging from individuals, SMEs and private clients up to UK universities and biotechnology start-ups. He also acts for EU and US genomics and academic institutions.

Simon chaired CIPA’s Life Sciences Committee for 20 years and relinquished that role earlier this year. He still Chairs the epi Biotech committee. He is a member of CIPA’s Council, Patents Committee and International Liaison Committee. He is a member of epi Council and the By-Laws committee and has been selected to be a member of SACEPO.

He is currently the President of CIPA for 2026.

He enjoys wine, gigs, playing the sax, running and cycling.

.